Quality Control • July 29, 2026 • Lucas Xu, Owner and Production Quality Control Manager
A practical note from Lucas Xu on why raw peptide material, batch documents and lyophilization process control should be reviewed before comparing suppliers only by price.
In many RFQ conversations, buyers ask me directly: “Can you send the current batch COA?”
I understand why they ask this. In peptide sourcing, no serious buyer wants to place an order without documents. But for custom filling and lyophilized peptide projects, there is one point that often needs to be explained first:
A raw material COA shows the quality of the peptide raw material before filling and lyophilization. A finished product COA shows the test results after that batch has gone through production, filling, lyophilization and packaging.
In a custom B2B project, the raw material COA can be reviewed first. The finished batch COA can only be generated after sample preparation or production and testing. This does not mean the supplier has no quality system. It simply means the finished product batch does not exist before production.
One reason I often explain this to buyers is price.
Sometimes our quotation is higher than another supplier's quotation. From the buyer's side, the products may look similar. The product name may be the same. The target purity may also look similar.
But the raw material specification may be very different.
A higher-grade peptide raw material can cost much more than a lower-grade material. The difference may come from purity, peptide content, molecular weight confirmation, impurity profile, batch consistency and documentation completeness.
So when our price is higher, it does not always mean we are taking more profit from the customer. It may simply mean the raw material level is different.
A good lyophilization facility is very important.
It controls the production environment, water system, filling process, lyophilization cycle, vial and stopper selection, capping, batch records, appearance, packaging and process risk.
I usually tell buyers that lyophilization is a process step, not a quality upgrade machine.
But lyophilization cannot turn poor raw material into high-quality finished product.
If the raw peptide material has poor purity, low peptide content, unclear identity or unstable impurity profile, a mature lyophilization process cannot fully solve the original material problem.
A clean and beautiful lyophilized cake may look good, but appearance alone does not prove that the raw material quality is high.
A raw material COA / quality documents review helps buyers understand peptide raw material quality before filling and lyophilization. Finished product COA or finished batch COA shows the tested result after production, filling, lyophilization and packaging.
It may help answer questions such as:
For custom B2B work, this is the starting point of quality review.
If the raw material itself is weak, the finished product quality will be limited from the beginning.
A finished product COA is different.
It is generated after production, filling, lyophilization and packaging. It reflects the result of a specific finished batch.
Some buyers may call this a lyophilized peptide COA, finished product COA or finished batch COA, depending on how the document is named.
This means a finished product COA cannot usually be provided before the batch exists.
For custom projects, a buyer may first review the raw material COA. After sample preparation or production, further batch testing can be arranged based on the agreed project scope.
They are related, but they are not the same.
In a mature lyophilization project, the facility mainly controls process-related risks.
A qualified and mature facility should have systems to manage these risks.
However, this should not be written as an absolute guarantee. Microbial and endotoxin risks are generally controlled through process management and batch testing. The specific result still depends on the actual batch and agreed testing requirements.
When the lyophilization process is mature and stable, many differences in the finished product come back to the raw peptide itself.
The raw peptide can affect HPLC purity, peptide content, molecular weight confirmation, impurity profile, raw material stability, finished product cost, batch consistency and later third-party testing results.
That is one reason two suppliers may offer very different prices for what looks like the same product.
The buyer may see the same product name, but the raw material level may not be the same.
We have seen buyers choose a lower-priced supplier because the quotation looked more attractive.
In one case, a buyer from South Africa focused mainly on low price. The supplier used lower-grade raw material, and later the finished products were not stable enough for the buyer's expectations.
In another case, a buyer from Brazil believed that a GMP-level lyophilization facility could solve almost every quality problem. But a good facility cannot replace the quality of the raw peptide material.
Because of cases like these, we prefer to discuss raw material documents, project requirements and batch testing scope before production, instead of only comparing price.
Before comparing quotations, buyers should ask:
These questions help buyers compare suppliers more fairly.
A lower price may be suitable for some projects. But if the buyer needs stable quality, repeat batches and serious documentation, the raw material level should not be ignored.
Aurchain Biotech supports qualified B2B buyers with peptide sourcing, custom production coordination and quality document discussion.
Raw material COA can often be reviewed before production. Finished batch documents can be discussed based on sample preparation, production status and testing requirements.
Not every project includes every test by default. Different projects require different documentation scopes, and the requirements should be confirmed before production.
Aurchain Biotech does not provide guidance for personal use or applications outside qualified B2B projects. Our communication is limited to B2B sourcing, quality documents and batch review.
A good lyophilization process can protect and present the material well, but it cannot replace the quality of the raw peptide itself.
For B2B buyers, raw material COA and finished product COA should both be understood correctly.
If the raw material is not good enough, the finished product will already be limited before lyophilization starts.
In serious peptide sourcing, the cheapest quotation is not always the safest quotation. The better question is:
No. Raw material COA shows the quality of the peptide raw material before production. Finished product COA reflects the tested result after filling, lyophilization and packaging.
Usually no. For custom projects, the finished batch COA can only be generated after the batch is produced and tested.
No. A mature lyophilization facility can control process-related risks, but it cannot replace the quality of the raw peptide material.
The difference may come from raw material grade, peptide content, purity, molecular weight confirmation, documentation scope, production process and testing requirements.
No. Testing requirements depend on product type, quantity, project requirements and buyer documentation needs. The scope should be confirmed before production.
Request B2B document review
Send product name, specification, quantity, destination country, packaging requirements and documentation needs. Aurchain Biotech will review your B2B RFQ and provide practical B2B sourcing options.
Related blog: Why Peptide Purity Is Not the Same as Peptide Content
Send a B2B RFQ